Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

In PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer, inavolisib plus palbociclib–fulvestrant led to significantly longer progression-free survival than placebo plus palbociclib–fulvestrant.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology